IHS Chemical Week

EnviroTech :: Biotech

Lonza Joins DSM as Manufacturer of Biopharma Drug for Agennix

3:55 AM MDT | April 12, 2012 | Alex Scott

Lonza has agreed to supply Agennix (Heidelberg, Germany), a biotech firm, with commercial quantities of talactoferrin, Agennix’s trial drug for the treatment of non-small cell lung cancer (NSCLC). As part of the deal, Lonza will also develop a biotech process for manufacturing the drug. Financial terms were not disclosed. Talactoferrin is an oral Dendritic Cell Mediated Immunotherapy (DCMI) drug. It is the first drug candidate of its type and currently is in phase III trials for treating NSCLC. Lonza will manufacture commercial quantities of...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa